In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Robust Times for Diagnostic Companies

Executive Summary

The diagnostic industry's buoyant health was evident at this year's American Association for Clinical Chemistry meeting in Los Angeles. Floor space was sold out and attendance hit a record. In contrast to a malaise in the industry through much of the 1990s, diagnostics now have reimbursement, demographic, and labor shortage trends in their favor. At $24.9 billion in revenues, experts say the industry is poised to deliver another year of double-digit growth, following an 11% gain in 2003.

You may also be interested in...



Status Check: Point-of-Care Testing in Hospitals

The in vitro diagnostics industry has looked for years to point-of-care testing in hospitals as a growth segment. The premise is sound--easy-to-use tests performed near the patient will yield faster results that enable physicians to make better on-the-spot treatment decisions. In reality, hospital demand is increasing, but not as fast as expected. A recent survey of one-third of US hospitals with 150 beds or more, by Enterprise Analysis Corp. seeks to understand POCT usage and demand trends.

On the Verge of a Deal for Dade Behring

A year ago, Dade Behring, the nation's sixth largest diagnostics company, was facing a huge debt and very angry debt holders. Now, the company seems close to a deal that would allow it to cut the debt in half (to about $750 million) and give debtholders full ownership of Dade Behring. The company would file a voluntary pre-packaged bankruptcy in federal court, which would also enable it to start trading securities on the public equities market. Nothing is finalized, but sources say the company is confident it will prevail. Meanwhile, its financial performance is picking up, with strong growth in all core product lines.

Dade Behring's Recap Plans

For more than a year, Dade Behring has been wading through a financial morass that is likely to lead to bankruptcy, a sale of assets, or a reorganization of capital structure. As concerns mount about its long-term prospects, Dade Behring and its lenders are seeking to restructure the company's burdensome long-term debt. While stubborn lenders have been unwilling to accept less than a near-to-full return on their investment, several events this spring seem to be motivating them to be more flexible.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV002412

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel